share_log

Aptevo Therapeutics Shares Drop 28% After More Than Doubling Tuesday

Aptevo Therapeutics Shares Drop 28% After More Than Doubling Tuesday

Aptevo治疗公司股价在周二上涨逾一倍后下跌28%
Dow Jones Newswires ·  2021/11/24 10:30

By Chris Wack

克里斯·瓦克(Chris Wack)著

Aptevo Therapeutics Inc. shares were down 28% to $12.31 Wednesday, one day after rallying following news from the company that a patient in a Phase 1b study of its lead proprietary drug candidate APVO436 in acute myeloid leukemia had a complete remission.

Aptevo治疗公司(Aptevo Treateutics Inc.)股价周三下跌28%，至12.31美元，此前一天，该公司传出消息称，其主要专利候选药物APVO436治疗急性髓细胞白血病的1b期研究中的一名患者完全缓解。

Volume for the stock was 5.2 million shares at 10:15 a.m. ET, compared with a 65-day average volume of 2.6 million. The stock hit its 52-week low of $6.38 on Monday and closed Tuesday's session up 163%.

截至上午10点15分，该股成交量为520万股。ET，而65天的平均成交量为260万。该股周一触及52周低点6.38美元，周二收高163%。

The company said one high-risk patient achieved a complete remission after one cycle of therapy, without evidence of overt toxicity.

该公司表示，一名高危患者在一个周期的治疗后完全缓解，没有明显毒性的证据。

Aptevo said the goal of the multi-center, multi-cohort study is to determine if APVO436 treatments can improve the quality of remission in high-risk patients by reducing the residual chemotherapy-resistant measurable residual disease burden.

Aptevo说，这项多中心、多队列研究的目标是确定APVO436治疗是否可以通过减少残留的化疗耐药的可测量的残余疾病负担来提高高危患者的缓解质量。

Write to Chris Wack at chris.wack@wsj.com

写信给克里斯·瓦克(chris.wack@wsj.com)

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发